NCT05469828: Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 30 planned
- Started
- 1 Jul 2024
- Primary completion
- 1 Jul 2028
- Arms
- treatment
- Results
- None posted
- 22 Jul 2022: Trial registered